Welcome to the Marbach Castle Drug-Drug Interaction Workshop Series
The DDI workshop series is a non-profit programme to exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
The overall objective of the international Marbach Castle DDI Workshop series is to improve and disseminate the scientific knowledge about drug-drug interactions (incl. food-drug and herb-drug interactions), and to foster communication for efficient preclinical and clinical investigation of DDIs across disciplines and organisational boarders.
The goal is safer use of pharmaceutical products especially in geriatric and medically complex patient populations with various co-morbidities and increasing poly-pharmacotherapy.
Registration is Open – DDI Workshop 2025
The upcoming Workshop will take place from June 1th to 3rd, 2025.
The Workshop Programme 2025
Now in its 15th year, the Marbach Workshop continues to offer a comprehensive exploration of timely and pivotal topics in the study of drug-drug interactions (DDIs) and dealing with them in modern clinical settings.
On day 1, the Workshop will commence with a session addressing possibilities and difficulties for personalised DDI management in clinical versus such provisions as part of the drug development practice. Key presentations will cover the implementation of PBPK to enhance individualized dosing in clinical settings and understanding the distinct DDI landscapes in various disease populations when they act as covariates in determining differences in DDI that is seen in healthy volunteers.
A subsequent session will critically examine the respective roles of static and dynamic modeling approaches in assessing DDIs. Presentations will debate pros and cons of each practice, and prudency of waivers on clinical DDI studies based on their application.
The third session will focus on managing DDIs caused by cytokine storms, a complex area with significant implications for patient safety. Presenters will provide case studies on using PBPK modeling to address cytokine storm-related DDIs, as well as discussions on the model predictability and limitations. Attendees will have the opportunity to explore real-world applications and debate the utility of PBPK in these high-stakes clinical scenarios.
On the second day, the Workshop will spotlight the potential role of artificial intelligence (AI) and natural language processing (NLP) in DDI research. Presentations will highlight emerging AI applications, including their impact on DDI assessment and case studies showcasing AI-enabled advancements. The closing session will delve into microphysiological systems (MPS) and their relevance in preclinical DDI studies. Experts will discuss the utility of MPS in generating physiologically relevant data for DDI assessment and enhancing in vitro to in vivo extrapolations.
As with previous meetings, selected posters will be given opportunity of short oral presentation during the workshop and early submission of abstracts for posters are highly encouraged.
Throughout the event, each session will facilitate interactive discussions, and attendees are encouraged to submit abstracts for poster presentations. As always, the Workshop’s topics will be addressed by leading international scientists, regulators, and industry experts, promoting a unique environment for knowledge exchange and networking.
The Workshop Organizers
Robert Hermann, MD FCP
Amin Rostami-Hodjegan PhD, FCP
Ping Zhao, PhD
Karen Grave-Hermann, MSc
Supporting organisations
